PCSK9 and cardiovascular disorder: These variants have also proved valuable in identifying potential therapeutic targets: confirmed LoF variants in the PCSK9 gene have been causally linked to low levels of low-density lipoprotein cholesterol6, and have ultimately led to the development of several inhibitors of PCSK9 that are now in clinical use for the reduction of cardiovascular disease risk.